Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
45.77B
Market cap45.77B
Price-Earnings ratio
1.41K
Price-Earnings ratio1.41K
Dividend yield
Dividend yield
Average volume
1.50M
Average volume1.50M
High today
$350.44
High today$350.44
Low today
$336.06
Low today$336.06
Open price
$338.43
Open price$338.43
Volume
911.75K
Volume911.75K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 45.77B, Alnylam Pharmaceuticals(ALNY) trades at $346.47. The stock has a price-to-earnings ratio of 1410.61.

As of 2026-02-03, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $336.06 and $350.44. The current price stands at $346.47, placing the stock +3.1% above today's low and -1.1% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 911.75K, compared to an average daily volume of 1.5M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 4d
Has The Recent Pullback In Alnylam Pharmaceuticals Opened A Valuation Opportunity?

Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for...

Has The Recent Pullback In Alnylam Pharmaceuticals Opened A Valuation Opportunity?
TipRanks 4d
Alnylam price target lowered to $462 from $529 at BofA

BofA lowered the firm’s price target on Alnylam (ALNY) to $462 from $529 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid cap biotech...

Simply Wall St 5d
What Alnylam Pharmaceuticals's Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders

In recent days, Alnylam Pharmaceuticals has attracted attention as analysts highlighted strong recent growth from products like AMVUTTRA, GIVLAARI, and OXLUMO,...

What Alnylam Pharmaceuticals's Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
32.3%
Sell
0%

More ALNY News

Nasdaq 6d
Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

Key Points Alnylam will likely report strong sales growth for Amvuttra in its February quarterly update. Management should also provide news about the initiat...

Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.